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Rat mast ce ll granules contain a sp ectrum of enzymes 
as establish ed b y histochem ical techniques and subcel-
lular fractionation. However, 35% of t h e ,8-glucuroni-
d a se, 30% of the ,8-D-ga lactosidase, 14% of the ,8-h ex-
o saminidase and all of the acid phosphatase is not avail-
able for immunologic relea se from purified rat serosal 
mast ce lls, suggesting the presence of nonsecretory ly-
so somes containing the se acid h ydrolases. On the other 
hand, immunologic r e lease of the majority of chymase , 
,8-hex osaminidase, ,8-glucuronidase, ,8-D-ga lactosidase, 
and a r y lsulfatase A occurs in parallel with histamine 
and thereby localizes these substances to the r a t mas t 
ce ll secretory granule . A molecular model of the secre-
tory granule in the resting mast ce ll can now be con-
s truct ed in which h eparin proteoglyca n is the granule 
matrix to which chymase and probably other proteins 
are ionically bound. Inhibition of chymase by serotonin 
stored in its a ctive site and of chymase and acid hydro-
lases by their interaction with h eparin probably occurs . 
Histamine is stored by ionic linkage to carboxyl groups 
of protein and heparin. Micromolar amounts of heparin 
glycosaminoglycans, histamine, serotonin, chymase, ,8-
D -hexosaminidase, ,8-glucuronidase, a nd arylsulfatase A 
in secre tory granules of 106 mast cells a r e 0. 7-1.3 x 10- 3 , 
70-220 X 10- 3 , 0.9-28 X 10- \ 0.2-0.5 X 10-\ 0.9-2.7 X 
10- 6 , 0.1-0.3 x 10- 6 and < 8 x 10 -t~ , r esp ectively. In 
addition, the total protein available for calcium iono-
phore-induced r ele a se from 106 r a t m ast ce lls is about 60 
p.g, indicating tha t less than 50% of the granule prote in 
can be a ccounted for . R ecognition tha:t mast cell secre-
tory granules contain acid hydrolases indicates that they 
are modified lysosomes ; their specia l intracellula r a nd 
extracellular functions are dictated by the associa t ed 
novel constituents and the stimulus for a ctivation. 
A variety of enzymes have been localized to mast cell granules 
based upon histochemical techniques [1-4] and subcellular 
frac tionation [5- 8]. In addi tion, localization to the mast cell 
secretory granule is inferred when noncytolytic immunologic 
release of an enzyme occurs in parallel with histamine. This 
paper will review the enzymes which are localized to mast cell 
granules, the evidence for granule heterogeneity, and the cur-
rent molecular model of the secretory granule. Discussion will 
be restricted for the most part to the rat model system because 
of the extensive work performed in this species with relatively 
pure populations of mast cells. 
Chymase has a-chymotrypsin-like specificity and is quanti-
fied by hydrolysis of small synthetic substrates such as benzoyl-
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L-tyrosine-ethyl ester (BT EE) [9] or of proteins such as 12"1-
casein [10]. Histochemical evidence for its presence in rat mast 
cell granules was presented in 1954 [3]. Consistent with this 
localization was the observation that chymase co-sed.imented 
with the granule marker heparin, to which it binds t ightly at 
physiologic salt concentrations and from which it can be solu-
bilized by 1.0 N N aCl [5,10]. Functional evidence for the local-
ization of chymase to the secretory granule was obtained by 
showing the release of chymase from rat peritoneal mast cells 
in response to polymyxin B in parallel with release of histamine 
[11]. However, the net % release of chymase was only about 
15% of the net % release of histamine, indicating either hetero-
geneous compositions of secretory granules, distinct pools of 
subcellular granules, or cell association of chym ase after its 
release. T he latter possibility is t he case. In recent experiments 
in which mast cells were washed with a solution of high ionic 
strength, cell-associated but released chymase was solubilized 
without release of additional histamine. The consequent net % 
release of chymase is almost equivalent to that of histamine, 
thereby establishing chymase as a component of the secretory 
gr anule. 
Ostensibly identical chymases have been detected ih mast 
cells from rat skin [12], muscle [13], and serosal cavities [10]. 
Unlike bovine a -chymotrypsin, rat mast cell chymase is a single 
protein chain of 25- 29,000 molecular weight [10]. In addition, 
rat skin chymase is not inhibited by concentrations of either 
ovomucoid trypsin inhibitor or basic pancreatic trypsin inhibi-
tor which completely inhibit bovine a -chymotrypsin [12]. Fm-
ther, rat mast cell chymase from skeletal muscle has a differe nt 
amino acid sequence than bovine a-chymotrypsin [13]. .Chy-
mase is also inhibited by serotonin in vitro at concentrations 
predicted to be present in rat mast cell granules in vivo [10). A 
distinct chymase, designated rat mast cell protease II (RMCP 
II), has been identified in atypical mast cells of the gut and lung 
[14]. RMCP II has no immunologic cross reactivity with anti-
bodies to chymase from typical rat peri toneal mast cells, which 
is termed rat mast cell protease I (R MCP I ) . Of the first N-
terminal 51 amino acids, there is only a 75% homology between 
RMCP I and II, indicating their distinct genetic origins. 
Whether or not the intestinal cell which contains RMCP II is 
truly a mast cell is unclear because of the apparent bone marrow 
origin of this cell type in contrast to the mesenchymal origin of 
typical mast cells. Nevertheless, t he pur poseful presence of 
different ch ym ases in different areas suggests unique tissue 
specificities for both RMCP I and II. 
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In the resting rat mast cell, chymase is probably t ightly 
bound to the heparin matrix of the secretory granule and is 
inhibited by this interaction and by serotonin [10]. After de-
gi'anulation in vivo, serotonin is probably diluted such that it is 
no longer an effective inhibitor of this protease. Proteolytic 
degradation of large molecules such as casein is inhibited when 
chymase is complexed with heparin in vitro, but hydrolysis of 
smaller molecules such as BTEE is not [10]. Thus, without 
solubilization of discharged granules or hepa.rin/ chymase com-
plexes in vivo, the substrate specificity of released chymase 
may be restricted. Of particular interest with regard to mast 
cell pathobiology, is the capacity of a -chymot rypsin and by 
inference, chymase, to directly initiate noncytotoxic degi·anu-
lation of rat mast cells [15]. In addition, an a -chymotrypsin-like 
enzym e in human peripheral polymorphonuclear leukocytes 
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can cleave C3 and C5 to generate the anaphylatoxins C3a and 
C5a [16], suggesting at least 2 possible chymase-dependent 
amplification mechanisms for mast cell activation. Fwther, 
chymase from rat skin can initiate degradation of rat cartilage 
proteoglycans, presumably by proteolytic cleavage of the core 
protein [17]. 
(3-Hexosaminidase, an acid exoglycosidase, can be detected 
by cleavage of its synthetic substrate, p-nitrophenyl-N-acetyl 
glucosamine [18]. Two major isomeric forms of this enzyme, 
termed A and B, can be distinguished by chromatography on 
DEAE-cellulose [18]. Detailed studies of the 2 major isomers 
from the human placenta have revealed that they are tetramers, 
composed of 2 a and 2 (3 polypeptides (azfJz) for type A and 4 
(3 polypeptides ((34) for type B [19,20]. (3 chains have a molecular 
weight of 27,000 and have identical amino acid compositions in 
both isoenzymes, but for different isoenzymes they may have a 
variable carbohydrate content [21]. a chains have a molecular 
weight of about 25,000 and have an amino acid and carbohy-
drate composition [19] and a gene location [22] that are distinct 
from those for (3 chains. By loss of az and acquisition of f3 z 
polypeptides conversion of type A to type B may occw· under 
a variety of in vitro conditions including temperatures above 
20°C [23], freezing and thawing [24], and prolonged storage 
[19]. In humans, deficiency of type A is associated with Tay-
Sachs disease and deficiency of both A and B subtypes with 
Sandhoffs disease [25]. 
(3-Hexosaminidase has been detected in the rat mast cell 
granule by histochemical techniques [2], co-sediments with the 
secretory granule markers chymase and heparin after cell lysis 
[7,8], and is released from rat mast cells in parallel with hista-
mine by polymyxin B [11] and by immunologic challenge with 
rabbit anti-rat F(ab')z in a dose- and time-dependent fashion 
[26]. Comparison of the net % immunologic release of (3-hexos-
aminidase with that of histamine indicates that at least 86% of 
the rat mast cell content of (3-hexosaminidase is available for 
immunologic release and is therefore localized to the secretory 
granule. The predominant isomeric form of (3-hexosaminidase 
in the rat mast cell, as indicated by its chromatographic behav-
ior is type A and the A isomer is the predominant form released 
upon immunologic activation of the cells. 
(3-Glucuronidase is another acid exoglycosidase and can be 
detected by cleavage of phenolphthalein-(3-D-glucuronide [27]. 
Two major isomeric forms, microsomal and lysosomal, are 
found in rodent tissues and can readily be distinguished by 
their distinct electrophoretic mobilities [28]. Both isomeric 
forms are tetramers composed of polypeptides with similar 
amino acid compositions and molecular weights of about 75,000, 
but the isomers differ in their isoelectric points and possibly in 
their carbohydrate compositions [29]. Only the microsomal 
subtype has the capacity to bind to the microsomal membrane 
associated protein, egasyn, and is thereby retained in micro-
somal fractions [30]. Deficiency of the microsomal form in mice 
due to a defect concerning egasyn leads to no apparent pheno-
typic abnormalities, but deficiency in humans of (3-D-glucuron-
idase itself results in mucopolysaccharidosis type VII and severe 
morbidity [31]. 
(3-Glucuronidase has been associated with mast cell granules 
by its cosedimendation with the granule markers, heparin and 
chymase, after cell lysis [8] and is released in parallel with 
histamine by rabbit anti-rat F(ab'h in a dose- and time-depen-
dent manner [26]. Comparison of net % release of (3-D-glucu-
ronidase with that of histamine indicates that at least 65% of 
the cell content of (3-D-glucuronidase is available for immuno-
logic release and is therefore localized to the secretory granule. 
The only subtype extracted from rat serosal mast cells and from 
material released by immunologic activation of these cells is the 
lysosomal form as assessed by the concordance of its electro-
phoretic mobility with the lysosomal form of {3-D-glucuronidase 
present in a rat liver extract. 
(3-D-Galactosidase activity can be assessed by hydrolysis of 
p-nitrophenyl-(3-D-galactopyranoside [32]. Two lysosomal (3-D-
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galactosidases, A and B, and one neutral (3-D-galactosidase 
have been described in human liver (reviewed in reference 25) . 
Type A is a monomeric sialoglycoprotein with a molecular 
weight of 72,000, whereas type B is an aggregate of 600-800,000 
molecular weight which cross reacts with monospecific anti-
bodies to type A. Both lysosomal subtypes can bind to concan-
avalin A, exhibit augmented activity in the presence of salt, 
cleave galactose from GMl gangliosides and from asialofetuin 
and are deficient in the genetic diseases, GMl gangliosidoses. 
Neutral (3-D-galactosidase has a neutral pH optimum, does not 
bind to concanavalin A, does not cross react with antibodies to 
type A, has a molecular weight of 57,000, is present in humans 
with GMl gangliosidoses and fails to cleave GMl gangliosides 
and asialofetuin. 
(3-D-Galactosidase activity has been detected in purified rat 
serosal mast cells by cleavage of p-nitrophenyl-(3-D-galactopy-
ranoside (Schwartz LB, Austen, KF, unpublished results). Im-
munologic stimulation of these cells results in the net % release 
of (3-D-galactosidase in parallel with histamine, but at a ratio to 
histamine indicating that about 70% is granule-associated and 
available for release .. The relative proportions of types A and B 
acid (3-D-galactosidases and the neutral (3-D-galactosidase de-
tected in and released from rat mast cells has not been clarified. 
Arylsulfatase is subdivided into 3 types. Types A and B are 
lysosomal glycoproteins which preferentially hydrolyze p-nitro-
catechol sulfate (pNCS) at acid pH, and are inhibited by sulfate 
and phosphate but not by cyanide [36-44]. Arylsulfatase C 
preferentially hydrolyses p-nitrophenylsulfate and p-acetyl-
phenylsulfate, is inhibited by cyanide but not by phosphate and 
sulfate, and is located in microsomes [ 44].ln humans, deficiency 
of type A results in metachromatic leukodystrophy whereas 
deficiency of arylsulfatase B results in mucopolysaccharidosis 
type VI. Arylsulfatase A purified from rat basophil leukemia 
tumors has an isoelectric point of 4.2, a molecular weight of 
116,000 by gel filtration, and a pH optimum of 5.2 with pNCS, 
whereas arylsulfatase B purified from the same source had an 
isoelectric point of 6.4, a molecular weight of 50,000 and a pH 
optimum of 5.4 [ 40]. 
Arylsulfatases from rat mast cells had isoelectric points sim-
ilar to those from the basophil leukemia tumor and this differ-
ence permitted their separation and quantitation in complex 
biologic fluids by isoelectric focusing [7]. Rat mast cells were 
found to contain equal quantities of A and B arylsulfatases. 
The net % release of arylsulfatase from immunologically chal-
lenged rat mast cells, though occuning in parallel with hista-
mine, was consistently only 30-50% of that for histamine, even 
after a 1 N NaCl wash of the activated mast cells, indicating 
that at least one-half of arylsulfatase is not available for release. 
Analysis of released and residual material showed that arylsul-
fatase B remained entirely within the mast cells, whereas most 
of type A was available for release and was the only form found 
in released material [7]. Of particular interest with rega1·d to 
their role in immediate hypersensitivity reactions is the in vitro 
observation that arylsulfatases from a variety of sources can 
inactivate slow reacting substance of anaphylaxis (SRS-A), now 
considered to be a leukotriene [ 45] in a time- and dose-depen-
dent fashion; these enzymes in turn are inhibited by slow 
reacting substance in their hydrolysis of pNCS [ 40,42]. 
Superoxide dismutase can be detected by its ability to scav-
enge superoxide radicals and thereby inhibit reduction of test 
molecules such as cytochrome c [ 46] or nitro-blue tetrazolium 
dye by superoxide [ 4 7]. These radicals can be beneficial through 
their microcidal effects toward foreign organisms phagocytized 
by polymorphonuclear and mononuclear leukocytes or patho-
logic to most cells when unregulated [ 48-55]. The major by-
products of superoxide radicals from their reaction with super-
oxide dismutase include hydrogen peroxide and molecular ox-
ygen. Superoxide dismutase is ubiquitous in respiring cells and 
is usually found in cytoplasmic fractions. 
Superoxide radicals are generated during stimulation of rat 
mast cells by ionophore and anti-lgE and are rapidly metabo-
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lized by addition of exogenous superoxide dismutase. Prepara-
tions of mast cell granules also appear capable of generating 
small amounts of superoxide radicals. The presence of endoge-
nous superoxide dismutase in rat mast cells was demonstrated 
by detection of enzyme activity in polyacrylamide gels after 
electrophoresis of mast celllysates [56]. A small fraction of the 
cell content of enzyme activity was also detected in isolated 
granule preparations and in immunologically released material 
apparently tightly bound to heparin proteoglycan molecules, 
indicating t hat a portion of the superoxide dismutase may be 
localized to t he secretory granule. 
Peroxidase catalyzes the reduction of hydrogen peroxide to 
water and can be detected by the concomitant oxidation of a 
co-reactant such as 0-tolidine [57]. Biologic importance for this 
class of enzyme is well demonstrated in polymorphonuclear and 
mononuclear leukocytes where granular myeloperoxidase can 
catalyze microcidal halogenation of invading organisms in the 
presence of hydrogen peroxide and halide ·ions [58-61]. Peroxi-
dase was first localized to granules of rat serosal mast cells by 
histoch emical techniques [62]. Confirmation of this was ob-
tained by detection of a significant fraction of peroxidase activ-
ity tightly bound to isolated granule material and in material 
released by immunologic stimulation. Specificity for this partic-
ular class of enzyme was obtained by inhibition of rat mast cell 
granular peroxidase or rat mast cell peroxidase with cyanide 
and by showing that incubation of substrate with exogenous 
catalase resulted in failure to detect peroxidase activity from 
ionophore stimulated mast cells. 
Acid phosphatase is detected by cleavage of p-nitrophenyl-
phosphate and of ,8-2-glycerophosphate and is considered a 
marker of lysosomes in most tissues. Acid phosphatase activity 
has been observed in association with rat mast cell granules by 
histochemical techniques [ 4] and a fraction of this enzyme 
activity cosediments with rat mast cell granule markers, chy-
mase and heparin [8]. However, histochemical data obtained 
with immunologically stimulated rat peritoneal mast cells in-
dicated that the granules which contain acid phosphatase are 
not available for release [63]. Further, in recent experiments 
there was no net release of acid p-nitrophenylphosphatase 
activi ty when rat serosal mast cells were stimulated with rabbit 
anti-rat F(ab')2 to achieve greater than 50% net release of 
histamine (Chang M, Schwartz LB, Austen KF, unpublished 
results). 
CONCLUDING COMMENTS 
Based upon calculations of the availability for release of t he 
lysosomal enzymes discussed above, it is possible to predict the 
presence of a nonsecretory pool of granules t hat may function 
as lysosomes. Such lysosomal granules might contain in addi-
tion to acid phosphatase, about 14% of the cellular ,8-hexosa-
minidase, 35% of the ,8-glucuronidase, 30% of the ,8-D-galacto-
sidase, and all of the arylsulfatase B. Further, because of 
observations that lysosomes in other cell types contain chon-
droitin sulfate, which for rat serosal mast cells represents ::::10% 
of the cell proteoglycan (Metcalfe D, Austen KF, unpublished 
results) , the mast cell nonsecretory granule may also contain 
this macromolecule. Proof of distinct mast cell nonsecretory 
lysosomes will require their isolat ion and their separation from 
the secretory modified lysosomes. 
A molecular model of the composit ion and structure of the 
rat mast cell secretory granule has been proposed in which the 
molar ratios of heparin proteoglycan: chymase: serotonin: his-
tamine were estimated to be 1:40-55:42:1352 [10]. These data 
were obtained by measuring the esterase activity for BTEE of 
a solubilized granule-enriched fraction and converting the ac-
t ivity measured to J.tg of chym ase based upon the esterolytic 
activity of commercial bovine pancreatic a-chymotrypsin. The 
data have been recalculated using the specific esterolytic activ-
ity of chymase, purified to homogeneity, and the ranges of 
molar ratios obtained are 1:3-14:15-800:1100-6300, as detailed 
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Composition of secretory granules of rat serosal mast cells 
Heparin glycosaminoglycan 
Heparin proteoglycan protein 
core 
Total protein 
Chymase 
,8-D-hexosaminidase 
,8-D-glucw-onidase 
Arylsulfatase A 
Histamine 
Serotonin 
l'g/ 10" cells l'moles/ 106 cells 
25-50 
1-5 
60 
5-13 
0.1-0.3 
0.03-0.09 
< 1 
8-24 
0.2-6 
0.7-1.3 X 10- 3 
0.2-0.5 X 10-" 
0.9-2.7 X 10- 6 
0.1-0.3 X 10-b 
<8 X 10-u 
70- 220 x w-3 
0.9-28 X 10-3 
in the Table. Macromolecular heparin proteoglycan, shown to 
be about 750,000 molecular weight, is the structural matrix of 
the granule. This molecule has a protein core assumed to be 
about 2-10% of its molecular weight based on values determined 
for proteoglycan from rat skin [64] and bovine nasal cartilage 
[65]. Heparin glycosaminoglycan side chains of 40,000 molecular 
weight are covalently attached to this core. Rat. serosal mast 
cells contain 25- 50 p.g of heparin glycosaminoglycan/ 106 cells 
by quantitation with azure A, which corresponds to 0.7-1.3 X 
10- 3 p.moles of glycosaminoglycan side chains. The protein 
content of the secretory granules of 101; rat serosal mast cells as 
determined from the material released by stimulation with 
calcium ionophore is about 60 p.g (Riedel C, Schwartz LB, 
Austen KF, unpublished results). Chymase accounts for 5- 13 
p.g of protein or a mean of 0.4 X 10- 3 p.moles per 106 cells, 
indicating about 1 molecule of chymase per 2 heparin side 
chains. A t ight ionic linkage between the cationic chymase and 
the sulfate groups on heparin is indicated by the high ionic 
strength required to dissociate this complex in vitro and to 
solubilize chymase from the granule in vivo [10]. From 0.2- 6 
p.g or 0.9-28 X 10- 3 p.moles of serotonin [66] and 8-24 J.tg or 70-
220 X 10- 3 J.tmoles of histamine are present in 106 rat serosal 
mast cells. Serotonin is present in molar excess over chymase, 
which it inhibits in vitro and to which it may be bound in vivo, 
perhaps exerting a regulatory role. Histamine is present in 
about a 100-fold molar excess over heparin side chains and in 
a 1-2:1 ratio to uronic acid monomers in heparin . Histamine, 
most likely, is bound to available carboxyl groups of h eparin 
and protein as indicated by the pH of 4- 5 necessary for complete 
solubilization of histamine from isolated granules at low ionic 
strength [67]. Additional enzymes such as ,8-D-hexosaminidase, 
arylsulfatase A and lysosomal ,8-glucuronidase account for less 
than 5% of the granule protein on a weight basis as calculated 
from the molecular weights and specific activities of these 
enzym es purified from the rat basophil leukemia tumor. They 
are fully solubilized from t he granule matrix in physiologic 
buffers, but may associate more t ight ly with th e heparin matrix 
in the microenvironment of th e intact secretory granule of 
resting mast cells . Such associations may, in fact, be regulatory 
because at acid pH, h eparin is an inhibitor for most lysosomal 
acid hyrolases [68]. The contribution of peroxidase and super -
oxide dismutase to the protein content of the secretory granule 
h as not yet been determined. In summary, it is only possible to 
account for less than one-half of the protein available for release 
from rat mast cell secretory granules. 
The secretory granules are composed in part of mediators 
destined to act primarily in the extracellular environment such 
as histamine and serotonin. They also contain a matrix material , 
heparin proteoglycan, on which the constituents of the secre-
tory granule are organized and which also affects the solubili ty, 
diffusion, and activity of particular enzymes both inside the 
resting mast cell and in the extracellular milieu following de-
granulation. The acid hydrolases of the secretory granule have 
been associated with lysosomes in other cell types and their site 
of action is th ought to be primarily in t he acidic environment 
of intracellular phagolysoso.mes, where degradation of ingested 
glycosaminoglycans, glycoproteins and complex glycolipids may 
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occur [69]. However, release of lysosomal hydrolases has been 
observed from macrophages during their phagocytic response 
[70] and has been sp~culated to result in t~s~ue remodeling or 
to augm ent tissue inJury [71]. The recogn1bon that the mast 
cell secretory granule contains acid hydrolases and can ~orm 
phagolysosomes, indicates that this organelle is a modified 
primary lysosome which has special il!tracellular. and extracel-
lular fun ctions dictated by the associa ted constituen ts of the 
secretory granule and the stimulus for mast cell activation. 
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DISCUSSION 
DVORAK: Are the kinetics in the human mast cell model very similar 
to that of rat mast cell degranulation over a period of a few minutes? 
ENZYMES OF THE MAST CELL GRANULE 353 
AuSTEN: Thus studies were done at 1, 3, and 5 min but the 5 and 3 
min specimens are indistinguishable in the human system. 
DvoRAK: Do you get a lot of fusion of granules with each other or is 
it a discharge of individual granules? 
AusTEN: Both , but only after solubilization of the granule. 
DvoRAK: T hen this would be analagous to the rat mast cell where 
you do get these big clusters of granules fusing with each other. 
AUSTEN: One of the things I did not point out was that as the granule 
becomes solublized, it is twice the size it was when it was crystalline. 
GOLDYN E: H ave you looked at arachidonic acid metabolit ies in 
human mast cells? I ask this question because we have found that when 
we compare human monocytes with animal monocyte-macrophage 
lines, PGD2 seems more prevalent in animal lines as compared to their 
human counterpar ts where PGE2 appears more prevalent. 
AusTEN: We did look at the nonmast cell peritoneal cells and they 
are very different. We presume that they are monocyte-macrophages; 
they are not a substan tial source of prostaglandin D2 in the rat. 
JORDAN: You mentioned that heparin can inhibit activation of the 
alternative complement pathway. How and where in the sequence does 
this inhibition occur? And is it associated with the heparin fraction t hat 
has anticoagulant activity? 
AusTEN: The studies with heparin were done in 2 ways: In the fluid 
phase, heparin interferes with the association of C3b with B to make 
the amplification convertase C3bBb in the presence of D. Inhibit ion is 
equal, whether one is dealing with heparin that has anticoagulant 
activity or heparin that lacks anticoagulant activity. By affinity chro-
matography with ant i-thrombin Ill columns, we've compared 2 batches 
and found that they can have a 100-fold difference in their anticoagulant 
activity, and be exactly the same on a weight basis in capacity to inhibit 
fo rmation of the amplification convertase. In another set of studies in 
which heparin was coupled to the surface of an activating particle, such 
as zymosan, its activating capacity was lost. The coupling of an N-
sulfated mucopolysaccharide to a particle facilitates its capacity to take 
up the regulatory protein B1H. 
In the presence of bound C3b and this prevents progression of the 
system to form C3bBb. T his is interesting because many cells are 
believed to have heparan on their surface which is similar to heparin. 
The reason we did these experiments was because we are especially 
interested in the capacity of cell surface heparan to regulate the 
interaction of a cell during its life cycle with the alternative pathway 
proteins. 
